The Preliminary Study About Relationship Of RhoGDI And Paclitaxel-resistant Ovarian Cancer

ObjectiveTo explore the relationship between RhoGDI protein and paclitaxel-resistant ovarian cancer by detecting RhoGDI protein(Rho GDP dissociation inhibitin) expression in paclitaxel-resistant and sensitive ovarian cancer cell lines and clinical tissue samples in order to find a biochemical index that predicts paclitaxel-resistant ovarian cancer, and provide a new therapeutic target for the clinical paclitaxel resistance in ovarian cancer.Methods1. Dozens of differentially expressed proteins were filtered out on the basis of the proteomics technology compares protein expression profiling between paclitaxel-sensitant(SK-OV3/Taxol-25) and sensitive (SKOV3)ovarian cancer cell. RhoGDI protein which highly expressed in ovarian cancer paclitaxel resistant cell lines was selected as purpose protein, and the differential expression of RhoGDI in ovarian cancer taxol-resistant and sentitive cell lines was verified by Western blotting. 2. Adopt the method of ine study, twenty-eight patients with ovarian cancer were collected retrospectively, the patients were divided into the paclitaxel resistant group and sensitive group. RhoGDI Protein expression differences in the two groups were detected by immuno histochemical method detection, and the relationship of RhoGDI and Pathological grading and clinical staging of ovarian cancer was analyzed.Results1. The RhoGDI protein was expressed in SKOV3/Taxol-25and SKOV3cell lines, but it was significantly higher expressed in SKOV3/Taxol-25cell line than SKOV3cell line, the difference was statistically significant (P<0.05).2. The RhoGDI protein positive expression rate (80%) in paclitaxel-resistant ovarian cancer group was significantly higher than that in the other group (16.67%), The difference was statistically significant(P<0.05). RhoGDI expression was not correlated with ovarian cancer pathological grade and clinical stage,the difference was statistically significant(P>0.05). The RhoGDI protein positive expression rate (70%) in low differentiation of paclitaxel-resistant ovarian cancer group was significantly higher than that in the other group (10%), The difference was statistically significant(P<0.05).Conclusions 1.RhoGDI protein expression in paclitaxel-resistant ovarian cancer cell lines and paclitaxel-resisensitant tissue samples were significantly higher than paclitaxel-sensitive ovarian cancer cell and tissues which suggests that RhoGDI protein was correlated with paclitaxel-resistant ovarian cancer.2.RhoGDI has nothing to do with tumor grade, clinical phase;3.The much higher expression of RhoGDI protein in poor differentiation of paclitaxel-resistant ovarian cancer patients than that in sensitive group indicates that ovarian cancer patients in poorly differentiated together with RhoGDI protein highly expressed is more likely to have paclitaxel resistance.